금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Iranian missiles hit two UAE tankers in Hormuz — Reuters
The United Arab Emirates (UAE) Ministry of Defence said that two UAE national tankers, the Mombasa a...
Gold tumbles below $4,000 on Trump’s Iran port blockade move, US CPI data looms
Gold price (XAU/USD) remains under selling pressure near $3,995 during the early Asian session on Tu...
Veeco Instruments stock rallies 17% as follow-on order signals growing chip demand
SpaceX-Google cloud deal may point to Microsoft Azure upside: BNP
Dow Jones ETFs: Better Than S&P 500 & Nasdaq Now?
Rising rate fears are hurting tech-heavy indexes, but the Dow's value tilt and lower tech exposure may offer relative resilience.
Plenty of Data Ahead of CPI, SPCX
Investors look toward tomorrow's Inflation Rate and the SpaceX IPO Friday, but we have lots of economic data out this morning: Small Business Index, Trade Balance and Existing Home Sales.
CoreWeave Stock Tumbles 34% in a Year: What Should Investors Do Now?
CRWV falls 34%, but booming AI demand, a $99.4B backlog and NVIDIA ties keep investors debating its long-term potential.
How teens can turn a summer job into an extra $500,000 in savings when they’re older
Teens who don’t have summer jobs miss out on valuable work experience — and on prime years to invest their income.
BofA warns investors to take profits as 70% of the bank's bear market signals flash red
"Bear market signposts" should tell investors to take profits, according to Bank of America.
Jeff Bezos Is Chasing Elon Musk Into Africa to Build a Starlink Competitor
FEATURE SpaceX’s Starlink is, well, miles above its competition. That doesn’t mean competitors have given up. Jeff Bezos appears set on taking a slice of Elon Musk’s space pie. Amazon.com has select ...
MaxLinear Up 354% YTD: Is the Stock Still Worth Considering?
MXL has skyrocketed 353% YTD after a sharp 2025 drop, driven by optical data center momentum, strong Q1 results and a multi-year growth outlook.
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Acushnet (GOLF): Buy, Sell, or Hold Post Q1 Earnings?
Acushnet has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.7% to $90.56 per share while the index has gained 8%.
Novo Nordisk marks more than 3M Wegovy pill prescriptions